"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes." Therapeutic Advances in Endocrinology and Metabolism
NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
The most common problems were gastrointestinal, including nausea and vomiting
Upon dextrane sulfate (DS)-induced colitis, colonic Tff2, Tff3, Tgfb1 , and Tgfb3 mRNA levels are significantly lower in Glp1r / mice compared to wild-type controls (Yusta et al., 2015)
Patient-centered education and protocol adjustments are essential to ensuring effective colorectal cancer screening in the era of GLP-1s
Oral semaglutide (Rybelsus) is the only FDA-approved oral GLP-1 receptor agonist
